Literature DB >> 1928342

Neuronal uptake, metabolism, and release of tritium-labeled norepinephrine during assessment of its plasma kinetics.

G Eisenhofer1, M D Esler, D S Goldstein, I J Kopin.   

Abstract

The extent to which intravenously infused [3H]norepinephrine ([3H]NE) is stored within and released by sympathetic nerves (tracer recycling) was examined by assessment of its plasma concentrations and by those of its intraneuronal metabolite dihydroxyphenylglycol (DHPG). Tracer recycling, as assessed by perturbations to steady-state plasma [3H]NE, was not apparent in humans during sympathetic activation by orthostasis or exercise. During intense electrical stimulation of cardiac sympathetic nerves after an [3H]NE infusion in dogs, plasma [3H]NE was higher in coronary sinus than arterial plasma, consistent with tracer recycling by cardiac sympathetic nerves. The specific activity of released [3H]NE was similar to that of [3H]NE and [3H]DHPG in cardiac tissue, indicating that both released [3H]NE and [3H]DHPG were derived from the same pool of neuronally stored [3H]NE. During intravenous infusion of [3H]NE in humans, plasma [3H]NE reached a steady state within 12 min and remained constant, whereas plasma [3H]DHPG increased progressively, reflecting metabolism of an increasing amount of [3H]NE leaking from sympathetic vesicles. Plasma concentrations of [3H]DHPG approached or exceeded those of [3H]NE after the end of radiotracer infusions and in the venous drainage of the heart and liver. Thus, to avoid error during assessment of plasma [3H]NE kinetics, an analytical step should be employed to separate plasma [3H]DHPG from [3H]NE. Because [3H]DHPG is derived from [3H]NE within the neuron, the specific activity of neuronally stored [3H]NE could be assumed to be no higher than the specific activity of plasma [3H]DHPG. This provided a means to estimate the maximum extent of tracer recycling, thereby indicating that, during intravenous infusion of [3H]NE, tracer recycling contributed negligibly (less than 5%) to steady-state plasma [3H]NE at normal levels of sympathetic activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928342     DOI: 10.1152/ajpendo.1991.261.4.E505

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  The role of the sympathetic nervous system in linking obesity with hypertension in white versus black Americans.

Authors:  Pirooz Eslami; Michael Tuck
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

2.  Catecholamines 101.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2010-07-11       Impact factor: 4.435

3.  Effects of catechol-O-methyltransferase inhibition on the plasma clearance of noradrenaline and the formation of 3,4-dihydroxyphenylglycol in the rabbit.

Authors:  T Halbrügge; B Friedgen; J Ludwig; K H Graefe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

4.  Sympathetic discharge to mesenteric organs and the liver. Evidence for substantial mesenteric organ norepinephrine spillover.

Authors:  A Aneman; G Eisenhofer; L Olbe; J Dalenbäck; P Nitescu; L Fändriks; P Friberg
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

Review 5.  Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease.

Authors:  Gino Seravalle; Giuseppe Mancia; Guido Grassi
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-05-01

Review 6.  Obesity, hypertension, and sympathetic nervous system activity.

Authors:  D B Corry; M L Tuck
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 7.  Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics.

Authors:  M Esler; D Kaye
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 8.  Sympathetic nerve function--assessment by radioisotope dilution analysis.

Authors:  Graeme Eisenhofer
Journal:  Clin Auton Res       Date:  2005-08       Impact factor: 4.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.